Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3461767 · 2 trials · 2 indications
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3461767 | EXPERIMENTAL | LY3461767 administered subcutaneously (SC). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered subcutaneously (SC). |
| LY3461767 - Subcutaneous (SC) | EXPERIMENTAL | LY3461767 administered SC. |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC. |
| LY3461767 - Intravenous (IV) | EXPERIMENTAL | LY3461767 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY3461767 | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
| LY3461767 - SC | DRUG | Administered SC. |
| LY3461767 - IV | DRUG | Administered IV. |
| Placebo - SC | DRUG | Administered SC. |
Inclusion Criteria: * Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential * Have a body mass index (BMI) of \</= 45.0 kilograms per square meter (kg/m²) * Have chronic stable heart failure (New York Heart Association (NYHA) classification II and ...
LY3461767 is an investigational small molecule being studied for chronic heart failure with reduced ejection fraction. It was also evaluated in healthy participants to assess its safety and tolerability. The drug is in Phase 1 clinical development and is not approved for any use.
LY3461767 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and effects in healthy participants and in patients with chronic heart failure with reduced ejection fraction.
LY3461767 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in healthy participants and one in participants with chronic heart failure with reduced ejection fraction. The drug is investigational and has not been approved by regulatory authorities.
LY3461767 has been studied in two completed Phase 1 trials. NCT04352114 evaluated the drug in 48 healthy participants in the United States and Singapore. NCT04840914 evaluated it in 44 participants with chronic heart failure with reduced ejection fraction in the United States and Japan.
LY3461767 is the only name provided for this investigational drug. No alternative names have been reported. It is a small molecule being developed by Eli Lilly and Company for chronic heart failure with reduced ejection fraction.